JP7788129B2 - 癌化学療法を増強するための組成物および方法 - Google Patents

癌化学療法を増強するための組成物および方法

Info

Publication number
JP7788129B2
JP7788129B2 JP2019569215A JP2019569215A JP7788129B2 JP 7788129 B2 JP7788129 B2 JP 7788129B2 JP 2019569215 A JP2019569215 A JP 2019569215A JP 2019569215 A JP2019569215 A JP 2019569215A JP 7788129 B2 JP7788129 B2 JP 7788129B2
Authority
JP
Japan
Prior art keywords
selenium
fish oil
nutritional supplement
combination
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019569215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523370A5 (https=
JP2020523370A (ja
Inventor
シャー，ホウン・サイモン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hsia Houn Simon
Original Assignee
Hsia Houn Simon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hsia Houn Simon filed Critical Hsia Houn Simon
Publication of JP2020523370A publication Critical patent/JP2020523370A/ja
Publication of JP2020523370A5 publication Critical patent/JP2020523370A5/ja
Priority to JP2023108547A priority Critical patent/JP2023115357A/ja
Priority to JP2025235858A priority patent/JP2026026381A/ja
Application granted granted Critical
Publication of JP7788129B2 publication Critical patent/JP7788129B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2019569215A 2017-06-13 2018-06-13 癌化学療法を増強するための組成物および方法 Active JP7788129B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023108547A JP2023115357A (ja) 2017-06-13 2023-06-30 癌化学療法を増強するための組成物および方法
JP2025235858A JP2026026381A (ja) 2017-06-13 2025-12-05 癌化学療法を増強するための組成物および方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762519093P 2017-06-13 2017-06-13
US201762519096P 2017-06-13 2017-06-13
US62/519,093 2017-06-13
US62/519,096 2017-06-13
US201762595002P 2017-12-05 2017-12-05
US62/595,002 2017-12-05
US201862670275P 2018-05-11 2018-05-11
US62/670,275 2018-05-11
PCT/US2018/037274 WO2018231943A2 (en) 2017-06-13 2018-06-13 Compositions and methods for enhancing cancer chemotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023108547A Division JP2023115357A (ja) 2017-06-13 2023-06-30 癌化学療法を増強するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2020523370A JP2020523370A (ja) 2020-08-06
JP2020523370A5 JP2020523370A5 (https=) 2021-07-26
JP7788129B2 true JP7788129B2 (ja) 2025-12-18

Family

ID=64658652

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019569215A Active JP7788129B2 (ja) 2017-06-13 2018-06-13 癌化学療法を増強するための組成物および方法
JP2023108547A Pending JP2023115357A (ja) 2017-06-13 2023-06-30 癌化学療法を増強するための組成物および方法
JP2025235858A Pending JP2026026381A (ja) 2017-06-13 2025-12-05 癌化学療法を増強するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023108547A Pending JP2023115357A (ja) 2017-06-13 2023-06-30 癌化学療法を増強するための組成物および方法
JP2025235858A Pending JP2026026381A (ja) 2017-06-13 2025-12-05 癌化学療法を増強するための組成物および方法

Country Status (9)

Country Link
US (2) US10905725B2 (https=)
EP (1) EP3638247A4 (https=)
JP (3) JP7788129B2 (https=)
KR (2) KR20240171182A (https=)
CN (1) CN111556754A (https=)
CA (1) CA3066713A1 (https=)
IL (1) IL271328A (https=)
TW (2) TW202535473A (https=)
WO (1) WO2018231943A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL265786B (en) 2016-10-03 2022-09-01 Houn Simon Hsia Materials and methods for increasing radiotherapy against cancer
EP3638269B1 (en) 2017-06-13 2025-12-17 Houn Simon Hsia Nutritional supplement for enhancing cancer radiotherapy
US10905725B2 (en) * 2017-06-13 2021-02-02 Houn Simon Hsia Compositions and methods for enhancing cancer chemotherapy
US12029765B2 (en) 2017-06-13 2024-07-09 Houn Simon Hsia Compositions and methods for treating cancer
IL271327B2 (en) 2017-06-13 2024-11-01 Simon Hsia Houn Compositions for increasing tumor sensitivity to hyperthermia therapy
US20220175850A1 (en) * 2019-04-01 2022-06-09 Houn Simon Hsia Compositions and methods for cancer therapy
AU2021324673B2 (en) * 2020-08-10 2025-07-24 Houn Simon Hsia Compositions and methods for treating viral infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140294795A1 (en) 2013-03-28 2014-10-02 Houn Simon Hsia Nutritional Composition
CN105617358A (zh) 2015-12-29 2016-06-01 广州市戴菊科技发展有限公司 一种具有抗肿瘤功能的医用食品及其制备方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348483A (en) 1981-01-23 1982-09-07 Universal Foods Corporation Method for the production of chromium yeast
US4569836A (en) 1981-08-27 1986-02-11 Gordon Robert T Cancer treatment by intracellular hyperthermia
CA2010511A1 (en) 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
NZ248605A (en) 1993-05-28 1994-12-22 Abbott Lab Enteral nutritional product comprising protein and fat
US20020010144A1 (en) 1994-04-29 2002-01-24 Robert Sobol Enhancing the sensitivity of tumor cells to therapies
US5976548A (en) 1994-11-08 1999-11-02 Viva America Marketing, Inc. Nutritional supplement composition and use
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US6440464B1 (en) 1996-06-10 2002-08-27 Viva Life Science Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates
US6197295B1 (en) * 1996-09-25 2001-03-06 Viva America Marketing Corporation Dietary supplementation with, and methods for administration of yeast-derived selenium product
US5810888A (en) 1997-06-26 1998-09-22 Massachusetts Institute Of Technology Thermodynamic adaptive phased array system for activating thermosensitive liposomes in targeted drug delivery
CA2339473A1 (en) 1998-08-04 2000-02-17 John V. Kosbab Nutrient and therapeutic compositions for the treatment of cancer
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
US20050080468A1 (en) 2001-03-26 2005-04-14 Lawrence C. Christman Methods and apparatus for treating diseased tissue
EP1438971A4 (en) 2001-10-25 2005-01-12 Ttc Co Ltd IMMUNE AMPLIFIERS IN THERAPEUTIC THERAPY IN CANCER
NZ533737A (en) 2002-01-11 2006-02-24 Matthias Rath A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
US20040087490A1 (en) 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
AU2002951833A0 (en) 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
US7744930B2 (en) 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
US8663679B2 (en) 2004-04-29 2014-03-04 Abbott Laboratories Compositions for improving breast health in women
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US20060088574A1 (en) 2004-10-25 2006-04-27 Manning Paul B Nutritional supplements
US20070116802A1 (en) 2005-11-23 2007-05-24 Carl Germano High quality caloric composition
US8017147B2 (en) 2008-04-07 2011-09-13 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
US20090110674A1 (en) 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
WO2009157759A1 (en) 2008-06-23 2009-12-30 N.V. Nutricia Nutritional composition for improving the mammalian immune system
EP3011843A1 (en) 2008-09-19 2016-04-27 Nestec S.A. Nutritional support of the immune system during anti-cancer treatment
US8257694B2 (en) 2009-05-14 2012-09-04 Product Partners, Llc Nutritional compositions for reducing oxidative damage
KR20120065276A (ko) 2009-05-29 2012-06-20 뉴 챕터, 인코포레이티드. 지질 조성을 조정하기 위한 조성물 및 방법
KR101275724B1 (ko) 2009-12-09 2013-06-17 한국전자통신연구원 단일 기판 집적 회로 장치 및 그 제조 방법
WO2011094579A2 (en) 2010-01-29 2011-08-04 New Chapter Inc. Mushroom compositions and methods for making and using
JP5882889B2 (ja) * 2010-03-15 2016-03-09 国立大学法人 岡山大学 抗腫瘍剤
US20120010688A1 (en) 2010-07-09 2012-01-12 Lamb Karl J Implantable conductive element and method of use inhyperthermic treatment
US9669053B2 (en) 2010-07-26 2017-06-06 Chemotherapeutics, Llc Compositions and methods for enhancing the effectiveness of systemic, HIPEC, IP, and related cancer treatments
WO2012122295A2 (en) 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
WO2014054884A1 (ko) 2012-10-05 2014-04-10 연세대학교 산학협력단 민감화 물질을 포함하는 온열 치료용 조성물
US9072768B2 (en) 2013-01-22 2015-07-07 Kibow Biotech, Inc. Composition and method for increasing effectiveness of radiation or chemotherapy
US9107947B2 (en) 2013-01-31 2015-08-18 The Penn State Research Foundation Anti-cancer compositions and methods
WO2014159851A2 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Novel low density lipoprotein nanocarriers for targeted delevery of omega-3 polyunsaturated fatty acids to cancer
MX370055B (es) 2013-04-22 2019-11-29 Smartfish As Uso de una composición que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cáncer.
SG11201600657RA (en) 2013-07-31 2016-02-26 Meiji Co Ltd Nutritional composition for inhibiting growth of tumor
EP3033091B1 (en) 2013-08-16 2022-09-07 Versitech Limited Probiotic composition and use thereof in the prevention and treatment of hepatocellular carcinoma
US20170246136A1 (en) 2014-09-24 2017-08-31 OliVentures, Inc. Pharmaceutical product, medical food or dietary supplement for preventing cancer and inflammatory diseases
CN105641000A (zh) 2015-06-01 2016-06-08 深圳市康道生物有限公司 一种含灰树花提取物的抗肿瘤组合物及其制备方法
JP7411327B2 (ja) 2015-11-18 2024-01-11 サイバーグ・コンサルティング・リミテッド・ライアビリティ・カンパニー 天然抽出物を含有する組成物、ならびに皮膚および毛髪に対するその使用
JP6376186B2 (ja) 2016-08-04 2018-08-22 トヨタ自動車株式会社 サスペンションメンバ
IL265786B (en) 2016-10-03 2022-09-01 Houn Simon Hsia Materials and methods for increasing radiotherapy against cancer
CN106822560A (zh) 2017-04-07 2017-06-13 湖北工程学院 药物组合物及其制备方法
US10905725B2 (en) * 2017-06-13 2021-02-02 Houn Simon Hsia Compositions and methods for enhancing cancer chemotherapy
EP3638269B1 (en) 2017-06-13 2025-12-17 Houn Simon Hsia Nutritional supplement for enhancing cancer radiotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140294795A1 (en) 2013-03-28 2014-10-02 Houn Simon Hsia Nutritional Composition
CN105617358A (zh) 2015-12-29 2016-06-01 广州市戴菊科技发展有限公司 一种具有抗肿瘤功能的医用食品及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Anticancer Reseach, 2009年, vol.29, pp.2421-2426
PLOS ONE, 2013年, vol.8, no.1, pp.1-11, e52912

Also Published As

Publication number Publication date
EP3638247A2 (en) 2020-04-22
IL271328A (en) 2020-01-30
US10905725B2 (en) 2021-02-02
CN111556754A (zh) 2020-08-18
KR20240171182A (ko) 2024-12-06
TW201906633A (zh) 2019-02-16
TW202535473A (zh) 2025-09-16
KR20200079229A (ko) 2020-07-02
WO2018231943A2 (en) 2018-12-20
CA3066713A1 (en) 2018-12-20
US20190134102A1 (en) 2019-05-09
US12036246B2 (en) 2024-07-16
EP3638247A4 (en) 2021-03-03
JP2026026381A (ja) 2026-02-16
JP2023115357A (ja) 2023-08-18
KR102736425B1 (ko) 2024-11-28
US20210252076A1 (en) 2021-08-19
WO2018231943A3 (en) 2019-02-28
JP2020523370A (ja) 2020-08-06

Similar Documents

Publication Publication Date Title
JP7788129B2 (ja) 癌化学療法を増強するための組成物および方法
Mortezaee et al. NF‐κB targeting for overcoming tumor resistance and normal tissues toxicity
Dai et al. Dihydroartemisinin: a potential natural anticancer drug
Zahedi et al. The effect of curcumin on hypoxia in the tumour microenvironment as a regulatory factor in cancer
JP2025120284A (ja) 魚油とセレンとを含む栄養サプリメント
Cheikh et al. Lessons learned from the discovery and development of the sesquiterpene lactones in cancer therapy and prevention
Chen et al. Protective effect of Ganoderma (Lingzhi) on radiation and chemotherapy
Morin et al. Docosahexaenoic acid monoglyceride increases carboplatin activity in lung cancer models by targeting EGFR
Mokhtarian et al. The effect of saffron and its extracts on the treatment of breast cancer: A narrative review
JP7071272B2 (ja) がん治療における抗エストロゲン剤有効性の増強のための擬絶食の使用
JP7565295B2 (ja) 栄養サプリメント
Wang et al. Whey protein and flaxseed gum co-encapsulated fucoxanthin promoted tumor cells apoptosis based on MAPK-PI3K/Akt regulation on Huh-7 cell xenografted nude mice
Zhu et al. Selective intratumoral drug release and simultaneous inhibition of oxidative stress by a highly reductive nanosystem and its application as an anti-tumor agent
Baghli et al. Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol
Benedicto et al. Ocoxin as a complement to first line treatments in cancer
US20240358769A1 (en) Compositions and Methods for Treating Inflammation Associated with IL-6
HK40030492A (en) Compositions and methods for enhancing cancer chemotherapy
Upadhyay et al. Breaching the barriers of chemotherapeutics for breast cancer with alternative medicine
Lai et al. Chemosensitization of doxorubicin against lung cancer by nature borneol, involvement of TRPM8-regulated calcium mobilization
Aswathy et al. Inflammation as a Target in Cancer Therapy
Baghli Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular
Chamani nano-curcumin’s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression
HK40029109A (en) Compositions and methods for enhancing cancer radiotherapy
CN105535019A (zh) 一种治疗肝癌的含银杏酚药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230630

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230810

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251201

R150 Certificate of patent or registration of utility model

Ref document number: 7788129

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150